New Biomarker Could Revolutionize Early Diagnosis of Alzheimer’s?

Imagine waking up one morning and not recognizing the face staring back at you in the mirror.

Or forgetting the names of your children, your spouse, your closest friends.

For the millions of people worldwide living with Alzheimer’s disease, these heartbreaking moments are a daily reality.

As the most common form of dementia, Alzheimer’s disease affects more than 35 million people globally. It’s a progressive, neurodegenerative condition that slowly erodes a person’s memory, thinking skills, and ability to carry out even the simplest tasks.

And while there is no cure yet, a recent breakthrough in the search for early diagnostic tools is offering a glimmer of hope.

A study led by researchers at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona has identified a new biomarker that could help diagnose Alzheimer’s disease in its early, asymptomatic stages.

The molecule, known as miR-519a-3p, is a microRNA directly linked to the expression of the cellular prion protein (PrPC), which is known to be deregulated in people suffering from Alzheimer’s and other neurodegenerative diseases.

This groundbreaking discovery marks the first time that miR-519a-3p has been specifically linked to the decrease in cellular prion protein production during the progression of Alzheimer’s disease. And while the exact mechanism behind these changes is not yet fully understood, the identification of this biomarker opens up exciting new avenues for early detection and intervention.

Currently, most tests to diagnose Alzheimer’s disease are carried out after the onset of symptoms, when cognitive impairment is already present.

But by detecting miR-519a-3p in the early stages of the disease, doctors could potentially establish additional criteria for a more accurate diagnosis before irreversible damage has occurred.

“If our goal is to use miR-519a-3p as a biomarker to detect Alzheimer’s dementia in hypothetically healthy people, it is essential to ensure that its levels are not altered in other neurodegenerative diseases,” explains IBEC senior researcher Rosalina Gavín, associate professor at the University of Barcelona and co-leader of the study.

To address this, the researchers compared the levels of miR-519a-3p in samples from other tauopathies and Parkinson’s disease, confirming that the changes in this biomarker are specific to Alzheimer’s.

This specificity is crucial if miR-519a-3p is to be used as a reliable diagnostic tool in clinical settings.

The next step is to validate miR-519a-3p as a biomarker in blood samples from different cohorts of patients. If successful, this could pave the way for using the biomarker in the clinical diagnosis of Alzheimer’s disease through simple, non-invasive peripheral samples.

For the hundreds of thousands of people worldwide who struggle with Alzheimer’s disease, or who have loved ones affected by this devastating condition, the identification of miR-519a-3p as a potential early diagnostic tool offers hope.

While there is still much work to be done, this discovery brings us one step closer to a future where Alzheimer’s can be detected and treated in its earliest stages, before irreversible damage has occurred.

To a brighter future for all those affected by Alzheimer’s,

Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team

P.S. FDA pumps brakes on big pharma’s latest Alzheimer’s cash grab.

Sources:

Dayaneth Jácome et al. (2024). miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. DOI: 10.1016/j.bbadis.2024.167187